Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma.

Santoni, M; Paccapelo, A; Burattini, L; Onofri, A; Cascinu, S

Santoni, M; Paccapelo, A; Burattini, L; Onofri, A; Cascinu, S.

Affiliation

Santoni M; Department of Medical Oncology, Polytechnic University of the Marche Region, Azienda Ospedaliero-Universitaria, Ospedali Riuniti Umberto I-GM Lancisi and G Salesi, Ancona, Italy. mattymo@alice.it

Anticancer Res ; 32(3): 1099-101, 2012 Mar.

Article in En | MEDLINE | ID: mdl-22399639

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Brain Neoplasms/drug therapy; Glioblastoma/drug therapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Dacarbazine/administration & dosage; Dacarbazine/analogs & derivatives; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nitrosourea Compounds/administration & dosage; Organophosphorus Compounds/administration & dosage; Temozolomide

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Glioblastoma Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Anticancer Res Year: 2012 Document type: Article Affiliation country: Italy Country of publication: Greece

Search on Google

Add to My VHL

XML

PubMed Links